Natesto: payments to doctors
Payments that named Natesto as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $638K
- Providers
- 5,580
- Transactions
- 12,949
- Average per transaction
- $49
The per-transaction average — $49 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,580 providers the average total is $114, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Acerus Pharmaceuticals Corporation | $406,941 | 63.8% |
| Aytu Bioscience, Inc | $227,179 | 35.6% |
| Aytu Biopharma, Inc. | $4,093 | 0.6% |
| Endo Pharmaceuticals Inc. | $17 | 0.0% |